2,4-diamino-6-(bromomethyl)pyrido<3,2-d>pyrimidine hydrobromide | 85325-85-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2,4-diamino-6-(bromomethyl)pyrido<3,2-d>pyrimidine hydrobromide
• 英文别名: 2,4-diaminopyrido<3,2-d>pyrimidine hydrobromide；2,4-diamino-6-bromomethyl-8-deazapteridine hydrobromide；2,4-Diamino-6-bromomethylpyrido[3,2-d]pyrimidine hydrobromide；6-(bromomethyl)pyrido[3,2-d]pyrimidine-2,4-diamine;hydrobromide
• CAS: 85325-85-5
• 化学式: BrH*C₈H₈BrN₅
• 分子量: 335.001
• InChiKey: MIXZRGNJYQCZCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.66
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  90.7
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4-diamino-6-(bromomethyl)pyrido<3,2-d>pyrimidine hydrobromide 在 sodium formate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 120.5h， 生成 4-[(2,4-Diaminopyrido[3,2-d]pyrimidin-6-yl)methyl-formylamino]benzoic acid
  参考文献：
  名称：

  Synthesis and Potent Antifolate Activity and Cytotoxicity of B-Ring Deaza Analogues of the Nonpolyglutamatable Dihydrofolate Reductase Inhibitor N^α-(4-Amino-4-deoxypteroyl)-N^δ-hemiphthaloyl-l-ornithine (PT523)

  摘要：

  Six new B-ring analogues of the nonpolyglutamatable antifolate N-alpha-(4-amino-4-deoxypteroyl)-N-delta-hemiphthaloyl-L-ornithine (PT523, 3) were synthesized with a view to determining the effect of modifications at the 5- and/or 8-position on dihydrofolate reductase (DHFR) binding and tumor cell growth inhibition The 5- and 8-deaza analogues were prepared from methyl 2-L-amino-5-phthalimidopentanoate and 4-amino-4-deoxy-N-10-formyl-5-deaza- and -8-deazapteroic acid, respectively. The 5,8-dideaza analogues were prepared from methyl 2-L-[(4-aminobenzoyl)-amino]-5-phthalimidopentanoate and 2,4-diaminoquinazoline-6-carbonitriles. The K-i for inhibition of human DHFR by the 5-deaza and 5-methyl-5-deaza analogues was about the same as that of 3 (0.35 pM), 11-fold lower than that of aminopterin (AMT, 1), and 15-fold lower than that of methotrexate (MTX, 2). However the K-i of the 8-deaza analogue was 27-fold lower than that of 1, and that of the 5,8-dideaza, 5-methyl-5,8-dideaza, and 5-chloro-5,8-dideaza analogues was approximately 50-fold lower. This trend was consistent with the published literature on the corresponding DHFR inhibitors with a glutamate side chain. In colony formation assays against the human head and neck squamous carcinoma cell line SCC25 after 72 h of treatment, the 5- and 8-deaza analogues were approximately as potent as 3, whereas the 5,8-dideaza analogue was 3 times more potent. 5-Methyl and 5-chloro substitution was also favorable, with the 5-methyl-5-deaza analogue being 2.5-fold more potent than the 5-deaza analogue. However the effect of 5-methyl substitution was less pronounced in the 5,8-dideaza analogues than in the 5-deaza analogues. The 5-chloro-5,8-dideaza analogue of 3 was the most active member of the series, with an IC50 = 0.33 nM versus 1.8 nM for 3 and 15 nM for MTX. The 5-methyl-5-deaza analogue of 3 was also tested at the National Cancer Institute against a panel of 50 human tumor cell lines in culture and was consistently more potent than 3, with IC50 values in the low nanomolar to subnanomolar range against most of the tumors. Leukemia and colorectal carcinoma cell lines were generally most sensitive, though good activity was also observed against CNS tumors and carcinomas of the breast and prostate. The results of this study demonstrate that B-ring analogues of 3 inhibit DHFR activity and tumor cell colony formation as well as, or better than, the parent compound. In view of the fact that 3 and its B-ring analogues cannot form polyglutamates, their high cytotoxicity relative to the corresponding B-ring analogues of AMT is noteworthy.

  DOI：

  10.1021/jm980477+
• 作为产物：
  描述：

  6-carbomethoxy-8-chloro-2,4-dimethoxypyrido<3,2-d>pyrimidine 在 palladium on activated charcoal 锂硼氢 、 氨 、 氢溴酸 、 氢气 、 sodium acetate 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 25.0~175.0 ℃ 、6.08 MPa 条件下， 反应 165.0h， 生成 2,4-diamino-6-(bromomethyl)pyrido<3,2-d>pyrimidine hydrobromide
  参考文献：
  名称：

  来自卡氏肺孢子虫和弓形虫的二氢叶酸还原酶的2，4-二氨基吡啶并[3，2-d]嘧啶抑制剂。

  摘要：

  由以下化合物合成了六个先前未知的2,4-二氨基-6-（苯胺基甲基）-和2,4-二氨基-6-[（N-甲基苯胺基）-甲基]吡啶基[3,2-d]嘧啶（5-10）通过在室温下在存在或不存在NaHCO3的条件下，用适当的苯胺或N-甲基苯胺在二甲基甲酰胺中处理，来制备2,4-二氨基-6-（溴甲基）-吡啶并[3,2-d]嘧啶氢溴酸盐（11.HBr）。测试了化合物5-10作为卡氏肺孢子虫，弓形虫和大鼠肝脏中二氢叶酸还原酶的抑制剂，这是针对发现兼具高酶选择性和高效力的亲脂性非经典抗叶酸药物的一项较大努力的一部分。在所测试的六个类似物中，对弓形虫DHFR最有效和最具选择性的是2,4-二氨基-6-[（3'，4'，5'-三甲氧基-N-甲基苯胺基）甲基]吡啶基[3,2- dd嘧啶（7），IC50为0。0047 microM（针对该酶）与0.026 microM（针对大鼠肝酶）相比。7对刚地弓形虫DHFR的效价与曲美

  DOI：

  10.1021/jm00014a014

文献信息

• Synthesis and antifolate activity of 8,10-dideazaminopterin
  作者：Joseph I. Degraw、Lawrence F. Kelly、Roy L. Kisliuk、Yvette Gaumont、Francis M. Sirotnak

  DOI：10.1002/jhet.5570190674

  日期：1982.11

  A synthesis of 8,10-dideazaminopterin, using 2,4-diamino-6-bromomethyl-8-deazapteridine (2) as a key intermediate, is described. Condensation of the triphenylphosphinylide derived from 2 with p-formylbenzoyl-L-glutamate afforded a 9,10-dehydro-8,10-dideazaminopterin ester intermediate 5. Hydrogenation of the olefinic linkage and subsequent hydrolysis of the glutamate ester gave the title compound.

  描述了使用2,4-二氨基-6-溴甲基-8-脱氮庚啶（2）作为关键中间体的8,10-二氮杂氨基蝶呤的合成。衍生自2的三苯基次膦酰基与对甲酰基苯甲酰基-L-谷氨酸的缩合，得到9,10-脱氢-8,10-二氨基氮杂蝶呤酯中间体5。烯烃键的氢化和谷氨酸酯的随后水解得到标题化合物。8,10-Dideazaminopterin是一种有效的叶酸依赖性细菌生长抑制剂。作为来自L1210白血病细胞的二氢叶酸还原酶抑制剂，它的效力是甲氨蝶呤的16倍，并且在小鼠中显示出对L1210的强活性。
• Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
  申请人：Dana-Farber Cancer Institute

  公开号：US07056911B1

  公开（公告）日：2006-06-06

  The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention and particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection such as pneumocystis pneumonia, toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.

  本发明涉及药物活性化合物，以及利用或包含其中一种或多种这样的化合物的治疗方法和药物组合物。本发明的化合物特别适用于治疗或预防与寄生虫感染相关的疾病，如肺孢子菌肺炎、弓形虫病、隐孢子虫病、利什曼病和疟疾。
• US7056911B1
  申请人：——

  公开号：US7056911B1

  公开（公告）日：2006-06-06
• Synthesis and Potent Antifolate Activity and Cytotoxicity of B-Ring Deaza Analogues of the Nonpolyglutamatable Dihydrofolate Reductase Inhibitor <i>N</i>^α-(4-Amino-4-deoxypteroyl)-<i>N</i>^δ-hemiphthaloyl-<scp>l</scp>-ornithine (PT523)
  作者：Andre Rosowsky、Joel E. Wright、Chitra M. Vaidya、Henry Bader、Ronald A. Forsch、Clara E. Mota、Jorge Pardo、Cindy S. Chen、Ying-Nan Chen

  DOI：10.1021/jm980477+

  日期：1998.12.1

  Six new B-ring analogues of the nonpolyglutamatable antifolate N-alpha-(4-amino-4-deoxypteroyl)-N-delta-hemiphthaloyl-L-ornithine (PT523, 3) were synthesized with a view to determining the effect of modifications at the 5- and/or 8-position on dihydrofolate reductase (DHFR) binding and tumor cell growth inhibition The 5- and 8-deaza analogues were prepared from methyl 2-L-amino-5-phthalimidopentanoate and 4-amino-4-deoxy-N-10-formyl-5-deaza- and -8-deazapteroic acid, respectively. The 5,8-dideaza analogues were prepared from methyl 2-L-[(4-aminobenzoyl)-amino]-5-phthalimidopentanoate and 2,4-diaminoquinazoline-6-carbonitriles. The K-i for inhibition of human DHFR by the 5-deaza and 5-methyl-5-deaza analogues was about the same as that of 3 (0.35 pM), 11-fold lower than that of aminopterin (AMT, 1), and 15-fold lower than that of methotrexate (MTX, 2). However the K-i of the 8-deaza analogue was 27-fold lower than that of 1, and that of the 5,8-dideaza, 5-methyl-5,8-dideaza, and 5-chloro-5,8-dideaza analogues was approximately 50-fold lower. This trend was consistent with the published literature on the corresponding DHFR inhibitors with a glutamate side chain. In colony formation assays against the human head and neck squamous carcinoma cell line SCC25 after 72 h of treatment, the 5- and 8-deaza analogues were approximately as potent as 3, whereas the 5,8-dideaza analogue was 3 times more potent. 5-Methyl and 5-chloro substitution was also favorable, with the 5-methyl-5-deaza analogue being 2.5-fold more potent than the 5-deaza analogue. However the effect of 5-methyl substitution was less pronounced in the 5,8-dideaza analogues than in the 5-deaza analogues. The 5-chloro-5,8-dideaza analogue of 3 was the most active member of the series, with an IC50 = 0.33 nM versus 1.8 nM for 3 and 15 nM for MTX. The 5-methyl-5-deaza analogue of 3 was also tested at the National Cancer Institute against a panel of 50 human tumor cell lines in culture and was consistently more potent than 3, with IC50 values in the low nanomolar to subnanomolar range against most of the tumors. Leukemia and colorectal carcinoma cell lines were generally most sensitive, though good activity was also observed against CNS tumors and carcinomas of the breast and prostate. The results of this study demonstrate that B-ring analogues of 3 inhibit DHFR activity and tumor cell colony formation as well as, or better than, the parent compound. In view of the fact that 3 and its B-ring analogues cannot form polyglutamates, their high cytotoxicity relative to the corresponding B-ring analogues of AMT is noteworthy.
• 2,4-Diaminopyrido[3,2-d]pyrimidine Inhibitors of Dihydrofolate Reductase from Pneumocystis carinii and Toxoplasma gondii
  作者：Andre Rosowsky、Ronald A. Forsch、Sherry F. Queener

  DOI：10.1021/jm00014a014

  日期：1995.7

  Six previously unknown 2,4-diamino-6-(anilinomethyl)- and 2,4-diamino-6-[(N-methylanilino)-methyl]pyrido[3,2-d]pyrimidines (5-10) were synthesized from 2,4-diamino-6-(bromomethyl)-pyrido[3,2-d]pyrimidine hydrobromide (11.HBr) by treatment with the appropriate aniline or N-methylaniline in dimethylformamide at room temperature, with or without NaHCO3 present. Compounds 5-10 were tested as inhibitors

  由以下化合物合成了六个先前未知的2,4-二氨基-6-（苯胺基甲基）-和2,4-二氨基-6-[（N-甲基苯胺基）-甲基]吡啶基[3,2-d]嘧啶（5-10）通过在室温下在存在或不存在NaHCO3的条件下，用适当的苯胺或N-甲基苯胺在二甲基甲酰胺中处理，来制备2,4-二氨基-6-（溴甲基）-吡啶并[3,2-d]嘧啶氢溴酸盐（11.HBr）。测试了化合物5-10作为卡氏肺孢子虫，弓形虫和大鼠肝脏中二氢叶酸还原酶的抑制剂，这是针对发现兼具高酶选择性和高效力的亲脂性非经典抗叶酸药物的一项较大努力的一部分。在所测试的六个类似物中，对弓形虫DHFR最有效和最具选择性的是2,4-二氨基-6-[（3'，4'，5'-三甲氧基-N-甲基苯胺基）甲基]吡啶基[3,2- dd嘧啶（7），IC50为0。0047 microM（针对该酶）与0.026 microM（针对大鼠肝酶）相比。7对刚地弓形虫DHFR的效价与曲美